Novo Nordisk taps Claude AI to speed drug R&D in Anthropic partnership

- Novo Nordisk to use Claude Science AI workbench to accelerate research and drug development - Collaboration to feature custom AI tool creation, strict data controls, and ongoing human oversight 2026-09-16 On September 16, 2026, CoinDesk reported that Denmark’s Novo Nordisk is partnering with Anthropic to integrate Claude AI models—particularly the Claude Science workbench—into its research and development efforts. The goal is to harness artificial intelligence to streamline drug discovery, tackle complex scientific problems, and reduce the time it takes to deliver new medicines to patients. The partnership will focus on building custom AI tools, enforcing robust data governance, and ensuring that human experts remain closely involved in every stage of development. As a result, this strategy aims to enhance productivity and meet rigorous industry compliance standards. In addition, Novo Nordisk emphasized that the deal underscores its ambitions to lead in AI-driven healthcare and referenced previous collaborations with OpenAI and AWS as part of its wider digitalization roadmap. According to CoinDesk, deploying Claude Science represents a push to improve efficiency and innovation in Novo Nordisk’s R&D pipeline, and the collaboration is ongoing. Meanwhile, both companies are working on integrating customized solutions and upholding responsible AI use as they develop new treatments.